Secondary antifungal prophylaxis in hematological malignancy patients with previous invasive fungal disease.
10.7534/j.issn.1009-2137.2015.02.059
- Author:
Ming-Juan LIU
1
;
Wen-Rong HUANG
1
;
Li YU
2
Author Information
1. Department of Hematology and BMT center, Chinese PLA General Hospital, Beijing 100853, China.
2. Department of Hematology and BMT center, Chinese PLA General Hospital, Beijing 100853, China. E-mail: chunhuiliyu@yahoo.com.
- Publication Type:Journal Article
- MeSH:
Antifungal Agents;
Hematologic Neoplasms;
Humans;
Immune Tolerance;
Immunosuppression;
Mycoses
- From:
Journal of Experimental Hematology
2015;23(2):596-600
- CountryChina
- Language:Chinese
-
Abstract:
Invasive fungal disease (IFD) causes a high morbidity and mortality in patients with hematological malignancies. Reactivation of IFD after chemotherapy or hematopoietic stem cell transplantation (HSCT) is very common and associated with poor prognosis. Secondary antifungal prophylaxis (SAP) is effective in preventing IFD recurrence. With effective SAP, a history of IFD is not an absolute contraindication to allogeneic HSCT or continuation of high-dose chemotherapy. In recent years, a variety of antifungal drugs such as voriconazole, itraconazole, AmB and caspofungin have been found to be effective for SAP. However, its management during granulocytopenia and immunosuppression remains challenging. This review summarizes the current status of SAP in patients with hematological malignancies.
